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Abstract The allograft inflammatory factor-1 (AIF-1) is a 17
kDa interferon-Q-inducible Ca2+-binding EF-hand protein that is
encoded within the HLA class III genomic region. Three proteins
are probably identical with AIF-1 termed Iba1 (ionized Ca2+-
binding adapter), MRF-1 (microglia response factor) and
daintain. Considerable but not complete sequence identity with
AIF-1 has been described for IRT-1 (interferon-responsive
transcript), BART-1 (balloon angioplasty-responsive transcript),
and other, yet unassigned alternatively spliced variants. In this
review, genomic and functional characteristics of AIF-1-related
proteins are summarized and a common nomenclature is
proposed. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The allograft in£ammatory factor-1 (AIF-1) is a 17 kDa
interferon (IFN)-Q-inducible Ca2-binding EF-hand protein
that is encoded within the HLA class III genomic region [1]
and was originally cloned from activated macrophages in hu-
man (GenBank accession number U49392) and rat (GenBank
accession number U17919) atherosclerotic allogenic heart
grafts undergoing chronic transplant rejection (Fig. 1A) [2].
It was initially demonstrated that AIF-1 is a modulator of the
immune response during macrophage activation [1,2]. Three
proteins are probably identical with AIF-1 but complete func-
tional identity still remains to be established, Iba1 (ionized
Ca2-binding adapter) [3,4], MRF-1 (microglia response fac-
tor) [5] and daintain [41]. A range of proteins that share con-
siderable but not complete sequence identity with AIF-1 have
been described. Overexpression of IRT-1 (interferon-respon-
sive transcript) protein in vascular smooth muscle cells
(VSMCs) alters their morphology and dramatically reduces
their proliferative capacity [6]. Following balloon angioplasty
of rat carotid arteries, the BART-1 transcript was detected [7].
G1 (EMBL accession number HSY14768) has been cloned
from an Epstein^Barr virus-transformed lymphoblastoid cell
line, but has only been submitted as a protein sequence with-
out further characterization. A recent report has described the
cloning of two novel alternatively spliced variants of AIF-1 by
reverse-transcription polymerase chain reaction in peripheral
blood leukocytes and in macrophages [8]. In addition, data-
base analyses reveal a number of cloned and in part patented
sequences with modular homology to AIF-1 suggesting di¡er-
ential splicing from the AIF-1-encoding gene.
To identify AIF-1-related sequences, the AIF-1 sequence
was mapped to its genomic region located on chromosome
6. The encompassing sequences were identi¢ed and fragments
were compared with nucleotide and expressed sequence tag
sequences using the BLAST database retrieval algorithm [9].
Obtained fragments were then assigned to the respective ge-
nomic region and splice sites were identi¢ed using the HSPL
program [10]. Frameshifts were detected by sequence align-
ment. Signal peptide and pattern localization site analyses
were conducted using the SignalP, PSort, HMMTOP and
PIR algorithms and databases [11^14].
2. AIF-1 and its homologues Iba1, MRF-1 and daintain
AIF-1 was initially identi¢ed early and persistently in
chronically rejecting cardiac allografts but not in cardiac syn-
grafts and host hearts in the Lewis F344 rat model of chronic
cardiac rejection. In cardiac allografts AIF-1 transcripts and
protein localized to in¢ltrating mononuclear cells and AIF-1
transcripts could be upregulated by IFN-Q. Treatment with an
arteriosclerosis-attenuating diet de¢cient in essential fatty
acids or CTLA-4 Ig (which blocks lymphocyte activation)
signi¢cantly decreased AIF-1 transcript levels [1]. In addition,
AIF-1 mRNA was detected in endomyocardial biopsy speci-
mens from human heart transplants and immunostaining in
human heart allografts localized the AIF-1 gene product to
a subset of CD68 macrophages in the interstitial and peri-
vascular spaces suggesting that AIF-1 is involved in the
in£ammatory response associated with human cardiac trans-
plant rejection [2]. Another report showed that AIF-1 is
expressed at low levels in undamaged, at increased levels
1 day and 3 days, and again at low levels 7 days post balloon
angioplasty. AIF-1 is inducible in serum- and cytokine-stimu-
lated human smooth muscle cells and was found to be con-
stitutively expressed in lymphoid tissue and augmented by
mitogens [15]. Accordingly, AIF-1 has since then been used
as a di¡erentiation marker for activated monocytes during
graft rejection [16,17]. However, AIF-1 mRNA and protein
were also observed in medial vascular smooth muscle cells in
immunologic and mechanical models of arterial injury [18].
Comparison of AIF-1 transcripts from di¡erent species re-
veals a high grade of similarity suggesting high evolutionary
conservation (Fig. 1B).
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In the brain, a subset of microglial cells constitutively ex-
press AIF-1 [19]. Increased numbers of AIF-1-immunoreac-
tive macrophages/microglial cells were observed in focal hu-
man brain infarctions [20], human and rat traumatic brain
injury [21,22], in human gliomas [23], rat uveitis [24], follow-
ing injection of immunostimulatory CpG nucleotides [25], and
in in£ammatory lesions of a rat model of autoimmune disease,
autoimmune encephalomyelitis, neuritis, and uveitis [26]. Dur-
ing experimental therapy of these diseases with high doses of
recombinant autoantigens or with dexamethasone, a promi-
nent reduction of AIF-1-immunoreactive macrophages/micro-
glial cells was observed [27].
Three other proteins share widespread identical amino acid
sequences with AIF-1 but complete functional identity still
remains to be established: Iba1, MRF-1 and daintain. Iba1
of both rat (DNA DataBank of Japan accession number
D82069) and human (DNA DataBank of Japan accession
number D86438) origin has been reported to be exclusively
Fig. 1. Chromosomal location and homology of AIF family members. AIF-1 and splice variants are encoded within the HLA class III region
on chromosome 6 (A). Comparison of AIF-1 sequences reveals a high degree of homology between the di¡erent species (B). AIF-1, Iba1,
MRF-1 and daintain of rat, human, mouse and pig origin are identical proteins with only species-speci¢c amino acid di¡erences (C).
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Fig. 2. AIF splice variants IRT-1, G1, BART-1 and the transcript described by Hara et al. [8] are encoded in the same region of the BAT2
gene on chromosome 6. The modular architecture suggests that di¡erential splicing mechanisms are responsible for the production of individual
proteins. All variants contain a varying number of exons and transcripts. Frameshift mechanisms appear to at least in part participate in the
production of the di¡erent variants.
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expressed in cells of the monocytic lineage and to be associ-
ated with microglial activation in the brain (Fig. 1C) [3,4].
Iba1 expression was observed in a microglilal cell line [28],
in rami¢ed microglia of adult rat brain and in the normal
mouse olfactory bulb [29]. Accordingly, Iba1 was used to
di¡erentiate activated macrophages/microglial cells in brain
tumors [30], following axotomy [31], facial nerve axotomy
[4], manganese toxicity [32], ischemic axonal death in periven-
tricular leukomalacia [33], in£uenza A virus infection [34],
spinal cord injury in the rat [35] and focal cerebral ischemia
[36].
MRF-1 (DNA DataBank of Japan accession number
AB000818) cloned from rat tissues has been reported to be
upregulated in microglial cells following apoptotic neuronal
cell death [5]. Again, MRF-1 has been used to identify acti-
vated macrophages/microglial cells during their transforma-
tion to the rami¢ed type [37], following cerebral ischemia in
the rat brain [38], and following neurodegeneration after me-
chanical nerve injury in the rat [39].
Functional studies revealed that AIF-1 is secreted into the
blood stream during experimental autoimmune neuritis [40].
When injected intravenously in mice, daintain/AIF-1 inhibited
lower-dose glucose-stimulated insulin secretion with a con-
comitant impairment of the glucose elimination, whereas at
higher doses daintain/AIF-1 potentiated glucose-stimulated
insulin secretion and enhanced the glucose elimination [41].
In an in vitro model of rat muscle regeneration, addition of
recombinant AIF-1 to the culture medium of satellite cells
(myogenic precursors) resulted in a signi¢cant concentration-
dependent and reversible reduction of the total number of
cells expressing M-cadherin, a mediator of the di¡erentiation
process of skeletal muscle cells, the proliferation-associated
Fig. 3. AIF family members encode proteins that are characterized by a wide range of biologically active sites.
Fig. 4. Splice variant-speci¢c promoter region analyses revealed binding sites for a wide range of transcription factors suggesting that distinct
transcription factors are involved in the production of AIF splice variants.
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PCNA and the initiator of muscle di¡erentiation myogenin
[42]. Intricate and widespread cellular functions of AIF-1
have been described in VSMCs. Transfection and constitutive
expression of AIF-1 in a primary and a rat VSMC line results
in enhanced growth of those cells as measured by cell number
and is proportional to the amount of AIF-1 expressed. Con-
stitutive expression of AIF-1 results in a shorter cell cycle.
AIF-1 overexpression also permits growth of these cells in
serum-reduced media. Here, it was shown that the growth-
enhancing e¡ects of AIF-1 in VSMCs are dose-dependent
and mediated by its ability to bind calcium [43,44]. Iba1
was shown to colocalize with F-actin in membrane ru¥es
induced by macrophage colony-stimulating factor and in
phagocytic cups formed during zymosan phagocytosis. Ex-
pression of mutant Iba1 carrying either N- or C-terminal de-
letions or carrying a substitution in the calcium-binding do-
main suppressed the membrane ru¥ing and the phagocytosis.
Furthermore, Iba1 colocalized with a small GTPase Rac in
the membrane ru¥es and the phagocytic cups. The Iba1 mu-
tants also suppressed membrane ru¥ing induced by dominant
active Rac1V12, but do not a¡ect microspikes by Cdc42V12
and stress ¢bers by RhoAV14 [45]. Moreover, Iba1 possesses
actin-binding and -cross-linking activities. Inhibitory mutant
Iba1 that suppresses membrane ru¥ing had lost the actin-
cross-linking activity, and it inhibited the cross-linking activity
of intact Iba1 [46]. Interestingly, a new single nucleotide poly-
morphism within the promoter region of the human AIF-1
gene has recently been described. The polymorphism, de¢ned
by GenBank accession number AF097515, was characterized
as a C/T single base pair substitution at position 3932. The T
allele is associated with both HLA-DR2 and HLA-B7. Also,
this allele creates the consensus binding site for the E-box that
has high a⁄nity for the basic helix-loop-helix family of tran-
scription factors [47]. Using di¡erential display reverse-tran-
scription polymerase chain reaction (RT-PCR), Iba1 was
identi¢ed during rat testis development. Iba1 was detected
in spermatogonia, spermatocytes, and round spermatids in
adult rat testis but was speci¢cally expressed in the cytoplasm
of elongate spermatids as well as in residual bodies that are
ultimately engulfed by Sertoli cells ¢rst at week 4 in postnatal
development and then increased up to adulthood [48].
3. The AIF-1 splice variants IRT-1, BART-1, G1, and others
A range of proteins that share considerable but not com-
plete sequence identity with AIF-1 have been described (Fig.
2). IRT-1 encodes a basic protein that contains a leucine zip-
per motif, a core nuclear localization sequence, and a single
strongly hydrophobic region. Constitutive IRT-1 mRNA ex-
pression in human peripheral blood lymphocytes is reduced
Table 1
Proposal for a new nomenclature of the AIF family of proteins
New
name
Species Old
name
Date Type Authors Accession
number
Description
AIF-1 Human AIF-1 28.10.95 complete cds Utans, U., Arceci, R.J., Yamashita,
Y., Russell, M.E.
U17919 AIF-1
? Human AIF-1 16.03.96 complete cds Utans, U., Arceci, R.J., Yamashita,
Y., Russell, M.E.
U49392 Di¡ers from AIF-1 at
N-terminal end:
TGPPAKKAISELP s
TPPSQESPI
AIF-1 Mouse AIF-1 15.05.98 complete cds Watano, K., Iwabuchi, K., Fujii, S. AB013745 AIF-1
AIF-1 Pig Daintain 15.12.98 protein Chen, Z.W., Ahren, B., Ostenson,
C.G., Cintra, A., Bergman, T.,
Moller, C., Fuxe, K., Mutt, V.,
Jornvall, H., Efendic, S.
P81076 AIF-1
AIF-1 Chrysophrys
major
AIF-1 09.01.99 complete cds Miyata, M., Iinuma, K., Miyazaki,
T.
AB019540 AIF-1
AIF-1 Rat MRF-1 05.02.99 complete cds Tanaka, S. AB000818 AIF-1
AIF-1 Rat Iba1 06.02.99 complete cds Imai, Y. D82069 AIF-1
AIF-1 Human Iba1 07.02.99 complete cds Imai, Y. D86438 AIF-1
AIF-1 Mouse Iba1 11.11.99 complete cds Imai, Y., Ohsawa, K., Kohsaka, S. D86382 AIF-1
AIF-1 Pig AIF-1 10.12.00 partial cds Mentschel, J., Deininger, M.H. AF299326 AIF-1
AIF-1 Bos taurus AIF-1 08.04.01 complete cds Glover, M.D., Seidel, G.E. Jr. AF348450 AIF-1
AIF-2 Human IRT-1 26.06.98 complete cds Autieri, M.V., Agrawal, N. U95213 AIF-1 splice variant IRT-1
AIF-2 Human IRT-1 27.06.01 complete cds Iris, F., Bougueleret, L., Prieur, S.,
Caterina, D., Primas, G., Perrot, V.,
Jurka, J., Rodriguez-Tome, P.,
Claverie, J., Cohen, D., Dausset, J.
NM_004847 AIF-1 splice variant IRT-1
AIF-3 Pig G1 10.12.00 complete cds Mentschel, J., Deininger, M.H. AF299325 AIF-1 splice variant G1
AIF-3 Human G1 10.12.00 complete cds Deininger, M.H., Trautmann, K. AF299327 AIF-1 splice variant G1
AIF-3 Rat G1 10.12.00 complete cds Deininger, M.H., Schluesener, H.J.,
Trautmann, K.
AF299328 AIF-1 splice variant G1
AIF-3 Human G1 27.06.01 complete cds Iris, F., Bougueleret, L., Prieur, S.,
Caterina, D., Primas, G., Perrot, V.,
Jurka, J., Rodriguez-Tome, P.,
Claverie, J., Cohen, D., Dausset, J.
NM_032955 AIF-1 splice variant
AIF-4 Human none 10.12.00 partial cds Deininger, M.H., Trautmann, K.,
Schluesener, H.J.
AF299329 AIF-1 splice variant
originally described by
Hara et al.
AIF-5 Human none Biol. Chem.
380 (1999)
1333^1336
partial cds Hara, H., Ohta, M., Ohta, K.,
Nishimura, M., Obayashi, H.,
Adachi, T.
None AIF-1 splice variant
originally described by
Hara et al.
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when these cells are stimulated to proliferate. Overexpression
of IRT-1 protein in VSMCs alters their morphology and dra-
matically reduces their proliferative capacity [6].
Following balloon angioplasty of rat carotid arteries, the
BART-1 transcript was described. This message is undetect-
able in undamaged vessels, reaches maximal levels 3 days post
procedure, and reduces to half-maximal expression by 14 days
post angioplasty. Northern analysis of various rat tissues re-
veals tissue speci¢city and possible di¡erential processing.
BART-1 mRNA therefore appears to represent an inducible,
tissue-speci¢c transcript encoding a putative integral mem-
brane protein transiently expressed in response to vascular
trauma [7].
A recent report has described the cloning of two novel
alternatively spliced variants of AIF-1 by RT-PCR in periph-
eral blood leukocytes and in macrophages [8]. One variant
encodes an AIF-1 protein that lacks 14 amino acids corre-
sponding to one exon. The other variant encodes a truncated
AIF-1 protein due to a frameshift introduced by an 85-bp
insertion, and its C-terminal region di¡ers from that of
AIF-1.
4. Characterization of AIF-1 and its splice variants
AIF-1 is a IFN-Q-inducible Ca2-binding EF-hand protein
encoded within the HLA class III genomic region on chromo-
some 6 termed BAT2. Several proteins including Iba1 and
MRF-1 share amino acid homology with AIF-1 but their
relationship remained unresolved. Using database analyses,
we con¢rmed that AIF-1, Iba1, MRF-1 and daintain have
identical cDNA sequences. Inversely, AIF-1-related variants
IRT-1, BART-1, G1 and Hara-1 appear to be AIF-1 splice
variants that contain up to seven exons within the AIF-1
genomic locus. Interestingly, frameshifts appear to be at least
in part involved in the production of the di¡erent transcripts.
It is of note that splicing results in the di¡erential inclusion
of EF-hand, leucine zipper and hormone precursor
sites suggesting diverse and widespread biological functions
(Fig. 3). Analyses of the sequences immediately adjacent to
the transcription start site revealed binding sites for a wide
variety of transcriptional promoters and repressors thus giv-
ing evidence for widespread modulation of transcriptional reg-
ulation (Fig. 4).
5. Proposal for a new nomenclature of the AIF-1 protein family
Because a recent US patent has cloned a novel member of
the AIF-1 family termed AIF-3 (accession number E29047),
we think the most useful and practicable way to rename AIF-
1 family proteins is by chronological assignment of the ¢rst
description of a coding cDNA. According to this system (Ta-
ble 1), AIF-1 is a 147-aa protein described ¢rst by Utans et al.
AIF-2 is the 132-aa protein previously assigned IRT-1 ¢rst
described by Autieri et al. AIF-3 is a 93-aa protein that was
initially described by Menschel et al. AIF-4 is the 57-aa partial
sequence ¢rst described by Hara et al., and ¢rst submitted by
Deininger et al. AIF-5 is the second variant initially described
by Hara et al., which has not yet been submitted to a data-
base. It is of note that both sequences submitted by Hara et
al. are partial cDNAs that encode a stretch of the AIF-encod-
ing gene that has never before been described to encode an
individual protein. The aberrant AIF-1 sequence (accession
number U49392) initially described by Utans et al. is not
included in this system, because con¢rmation is still lacking.
In addition, a range of patented sequences that were assigned
either AIF-1 or AIF-1 variant can be found in the databases.
Because their functional and sequence con¢rmation is still
lacking, they are not included in this system, either.
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